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a b s t r a c t
A LC–MSMS method for the simultaneous determination of tamoxifen, N-desmethyltamoxifen,
4-hydroxytamoxifen and endoxifen in dried blood spots samples was developed and validated. The
method employs an ultrasound-assisted liquid extraction and a reversed phase separation in an
Acquitys C18 column (1502.1 mm, 1.7 mm). Mobile phase was a mixture of formic acid 0.1% (v/v)
pH 2.7 and acetonitrile (gradient from 60:40 to 50:50, v/v). Total analytical run time was 8 min. Precision
assays showed CV % lower than 10.75% and accuracy in the range 94.5 to 110.3%. Mean analytes
recoveries from DBS ranged from 40% to 92%. The method was successfully applied to 91 paired clinical
DBS and plasma samples. Dried blood spots concentrations were highly correlated to plasma, with
rs40.83 (Po0.01). Median estimated plasma concentrations after hematocrit and partition factor
adjustment were: TAM 123.3 ng mL1; NDT 267.9 ng mL1, EDF 10.0 ng mL1 and HTF 1.3 ng mL1,
representing in average 98 to 104% of the actually measured concentrations. The DBS method was able to
identify 96% of patients with plasma EDF concentrations below the clinical threshold related to better
prognosis (5.9 ng mL1). The procedure has adequate analytical performance and can be an efﬁcient tool
to optimize adjuvant breast cancer treatment, especially in resource limited settings.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Tamoxifen (TAM) [trans-1-(4-β-dimethylaminoethoxyphenyl)-
1,2-diphenyl-1-butene] has been the mainstay hormonal treat-
ment for breast cancer for more than 30 years, with signiﬁcant
impact on the survival rates of patients. However, besides the
therapeutic beneﬁts of TAM in the general population, 30 to 50% of
patients under TAM pharmacotherapy have tumor recidives or
present resistance to the treatment [1].
The usual presentation of TAM is TAM citrate tablets, contain-
ing 10 or 20 mg of the pure trans isomer, with the recommended
posology of 20 mg per day. TAM pharmacologic activity is depen-
dent of its bioativation by cytochrome P 450 enzymes [2,3].
CYP3A4 and 3A5 convert TAM to N-desmethyltamoxifen (NDT),
this being the largest primary metabolic route. NDT undergoes 4-
hydroxylation via CYP2D6, being biotransformed into 4-hydroxy-
N-desmethyltamoxifen or (Z)-endoxifen (EDF). CYP2D6 also cata-
lyzes the metabolism of TAM to 4-hydroxy-TAM (HTF) [4]. The
antiestrogenic activity of TAM is mainly due to EDF, which, as HTF,
is up to 100 times more potent to inhibit the proliferation of
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estrogen-dependent cells, and usually have plasma concentrations
up to 6 times higher than HTF [5].
EDF plasma concentrations were widely variable among
patients, what could be explained by polymorphisms in the gene
encoding CYP2D6 and by interactions with enzyme modulating
agents, leading to insufﬁcient plasma EDF levels in many indivi-
duals [6]. Along CYP2D6, CYP3A and CYP2C9 enzymes were
related to EDF formation, but to a lesser extend [2]. Recently, Teft
et al. [7] described reduced EDF plasma concentrations during the
winter months, which was associated to low plasma 25-
hydroxyvitamin D levels. These authors suggested that CYP3A4
activity together with sunlight exposure is an underscored factor
in the evaluation of the therapeutic efﬁcacy of TAM.
In a recent clinical study, Madlensky et al. [8] exploited the
relation between the clinical outcome of hormonal therapy and
serum concentrations of TAM and its metabolites, suggesting that
adequate therapeutic outcome is dependent to the achievement of a
threshold EDF concentration. Patients presenting trough EDF plasma
levels above 5.9 ng mL1 had a 26% reduction of recurrences com-
paring with patients with EDF concentrations below this threshold.
These ﬁndings, along with the increasing knowledge about TAM
metabolism modulating agents, encouraged studies with individua-
lized dose adjustments, with increased doses for patients with
impaired EDF formation (30 or 40 mg day1) [9–11]. Moreover,
the metabolic ratio [NDF]/[EDF] has been described as an appro-
priate surrogate of CYP2D6 activity, rendering useful clinical infor-
mation about TAM metabolism [5]. Considering the available
evidence, therapeutic drug monitoring of TAM and its main meta-
bolites during hormonal therapy of breast cancer could be an
important tool to obtain optimal pharmacological response, re-
cognizing patients eligible to higher TAM doses or alternative
pharmacotherapy.
Several methods for the measurement of TAM and metabolites
in serum or plasma samples were described [6,12–14]. To obtain
these conventional samples, it is necessary to perform a phlebot-
omy in a proper facility, also considering pharmacokinetically
appropriated collection times. A novel option for therapeutic drug
monitoring that has been emerging recently is testing in dried
blood spots on paper (DBS), collected by ﬁnger prick [15–17],
mainly due to the stabilization of the analytes by drying and the
possibility of postal transportation, once DBS samples are usually
non-bio hazardous. Also, this novel matrix allows the possibility of
training patients to take their own samples and ﬂexible collection
times, more adequate to their personal posology [18].
The use of DBS for TAM and metabolites measurements could
be a very useful strategy to optimize the use of this drug in breast
cancer, potentially allowing continuous monitoring of EDF levels
during a long-time treatment, without requiring patients to come
to a specialized center. However, considering the small blood
volume present in a DBS obtained after a ﬁnger prick and the
low concentrations of TAM and metabolites, especially EDF, this
application requires highly sensitive analytical methods. In view of
the above, the objective of this study was to develop and validate a
method for determination of TAM and its metabolites NDT, EDF e
HTF in DBS using ultra performance liquid chromatography-
positive electrospray ionization tandem mass spectrometry and
evaluate its performance in clinical samples of breast cancer
patients.
2. Experimental
2.1. Reagents, materials and reference standard samples
Tamoxifen, 4-hydroxy tamoxifen e clomifen citrate (E/Z) were
acquired from Sigma (Saint Louis, USA). N-desmethyl tamoxifen
chloridrate and N-desmethyl-4-hidroxy tamoxifen (E/Z) were
obtained from Toronto Research Chemicals (North York, Canada).
Tris(hidroxymethyl)aminomethane was obtained from Nuclear
(Diadema, Brazil). Formic acid, metanol, acetonitrile, n-propanol
and hexane (60% n-hexane) were bought from Merck (Darmstadt,
Germany). Puriﬁed water was obtained from an Elga Purelab
Ultras system from Veolia Labwater (High Wycombe, UK). What-
man 903 paper was obtained from GE Healthcare (Westborough,
USA).Finger prick blood samples were collected using Medlances
Plus Special lancets (0.8 mm blade) from Medlance Plus Special
(Marietta, USA).
2.2. Preparation of solutions and standards
TAM, NDT and EDF (E/Z) stock solutions were prepared in
methanol to obtain a concentration of 1 mg mL1. The stock
solution of HTF was prepared in methanol to obtain a concentra-
tion of 0.1 mg mL1. Stock was diluted with methanol to obtain
intermediate solutions of EDF and HTF at 20 mg mL1 and inter-
mediate solutions of TAM, NDT e EDF at 40 mg mL1 (20 mg mL1
of the Z-fraction of EDF). Working solutions were prepared by
dilution of the intermediate solution with methanol. Calibration
samples were prepared in whole blood diluting working solutions
at 1:20 with whole blood free from the analytes, as described in
the linearity section. Clomifene citrate stock (internal standard, IS)
solution was prepared in methanol at 1 mg mL1 concentration.
Intermediate clomifene solutions were prepared by dilution of the
stock with methanol (10.0 mg mL1) and further diluted to
0.1 mg mL1. DBS extraction solution was prepared by dilution of
the clomifene intermediate (0.1 mg mL1) with methanol to obtain
a concentration of 0.1 ng mL1.
2.3. Sample preparation
Quality control and calibration samples were prepared by
pipetting 60 mL aliquots of spiked blood onto Whatman 903 paper
and leaving them to dry at room temperature for 3 h before
processing. DBS discs were obtained by perforation, using a
10 mm punch cutter, and two discs were used for extraction. Discs
were cut in half, transferred to polypropylene microtubes and
1000 μL of extraction solution was added (clomifene 0.1 ng mL1
in methanol), followed by 1 min vortexing. After 45 min h in an
ultrasonic bath, 850 μL of extract was transferred to a clean
polypropylene microtube and dried at 55 1C under a gentle stream
of air. The dried extract was recovered with 100 mL of mobile
phase, transferred to an autosampler vial and a 25 μL aliquot was
injected into the LC–MS/MS system.
2.4. UHPLC–MS–MS equipment and conditions
Samples were analyzed using a TSQ Quantum Access triple
quadrupole mass spectrometer with an electrospray source, coupled
to an Ultimate 3000 XRS UHPLC system, controlled by the Xcalibur
software, all from Thermo Scientiﬁc (San Jose, USA). Separation was
performed in an Acquity C18 column (1502.6 mm, p.d. 1.7 μm)
from Waters (Milford, USA), maintained at 50 1C and eluted at a
mobile phase ﬂow rate of 0.4 mL min1. The mobile phase con-
sisted of formic acid 0.1% pH 2.7 (eluent A) and acetonitrile plus 0.1%
formic acid (eluent B). Initial eluent composition was 60% A,
maintained for 3 min, and followed by a linear 1 min ramp to
50%, which was maintained for until 5.5 min. The mobile composi-
tion returned to 60% A at 6 min. Equilibration time was 2 min.
Injection volume was 25 μL. The MS conditions were as follows:
electrospray ionization (ESI), positive mode, capillary voltage of
4 kV; sheath gas, nitrogen at a ﬂow rate of 50 arbitrary units;
auxiliary gas, nitrogen at ﬂow rate of ten arbitrary units; collision
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gas, argon; vaporizer temperature, 400 1C; and ion transfer capillary
temperature, 220 1C. The scan time was set at 0.3 s per transition.
The following transitions were used for MRM acquisition: TAM m/z
372-72 (quantitation) and m/z 372-70 and 372-129 (qualiﬁca-
tion); NDT m/z 358-58 (quantitation) and m/z 358-129 and
358-178 (qualiﬁcation); EDF m/z 374-58 (quantitation), m/z
374-152 and 374-223 (qualiﬁcation); HTF m/z 388-72 (quanti-
tation) and m/z 388-129 and 388-223 (qualiﬁcation); IS (clomi-
fene) m/z 406-100 (quantitation) and m/z 406-72 and 406-58
(qualiﬁcation). Collision energies were 23, 19, 19, 24 and 24 eV for
TAM, NDT, EDF, HTF and IS, respectively.
2.5. Selectivity
Blank DBS samples obtained from 6 different human sources
were prepared as described above to check for the presence of
chromatographic peaks that might interfere with detection of
analytes or IS.
2.6. Benchtop stability
For estimation of stability of processed samples under the
conditions of analysis, control DBS samples were extracted as
described above, in sextuplicate. Quality control low (QCL) sam-
ples had TAM, NDT, EDF e HTF at 21.0; 45.0; 3.0 and 1.8 ng mL1,
respectively. Quality control high (QCL) samples had TAM, NDT,
EDF and HTF at 210.0; 450.0; 30.0 and 10.8 ng mL1, respectively.
The extracts obtained at each concentration were pooled. Aliquots
of these pooled extracts at each concentration were transferred to
autosampler vials and injected under the conditions of a regular
analytical run at time intervals of 1 h, during 12 h. Stability of
analytes was tested by regression analysis plotting absolute peak
areas corresponding to each compound at each concentration vs.
injection time. Using the obtained linear regression, the concen-
tration after 12 h was calculated. A decrease or increase of up to
10% in the measured peak areas was considered as acceptable.
2.7. Stability of analytes in DBS at varying temperatures
For evaluation of thermal stability of TAM and metabolites in
DBS samples, quality control DBS samples (QCL and QCH), pre-
viously described, were maintained at 20 1C, 25 1C e 45 1C and
analyzed (triplicate) on days 2, 6, 8, 10, 13, 15, 17 e 20 after spotting
in the paper. Stability was considered acceptable if all results were
within the range of 85–115% of the concentrations measured at the
beginning of the series.
2.8. Linearity
Aliquots of 950 μL blank blood (Hct 35%), were enriched with
50 μL of the corresponding stock solutions to obtain seven
calibration levels of samples containing TAM (300, 225, 150, 75,
30, 15, 7.5 ng mL1), NDT (600, 450, 300, 150, 60, 30, 15 ng mL1),
EDF (40, 30, 20, 10, 4, 2, 1 ng mL1) and HTF (50, 15, 10, 5, 2, 1,
0.5 ng mL1). Calibration samples were applied to Whatman 903
paper (1260 mL for each level), dried at room temperature and
analyzed within 24 h. Replicates (n¼6) at each concentration were
analyzed as described at item 2.5. Calibration curves were calcu-
lated relating the area ratios from TAM, NDT, EDF and HTF peaks to
the IS peak and with the nominal concentrations of the calibration
samples. Homoscedasticity of calibration data was evaluated with
F-test at the conﬁdence level of 95%. Curves were ﬁtted using
least-squares linear regression using several weighting factors
(1/x, 1/x2, 1/y, 1/y2). Calibration models were assessed using
coefﬁcients of correlation (r) and cumulative percentage relative
error (∑%RE) [19]. Daily calibration curves using the same
concentrations (single measurement at each concentration level)
were analyzed with each batch of validation and clinical samples.
2.9. Precision and accuracy
Aliquots of blank blood were enriched with methanolic solutions
and applied to paper to obtain quality control DBS samples containing
TAM, NDT, EDF and HTF at concentrations of 21.0; 45.0; 3.0 and
1.8 ngmL1, respectively (quality control low, QCL), 70.0; 150.0; 10.0
and 6.0 ngmL1, respectively (quality control medium, QCM) and
210.0; 450.0; 30.0 and 18.0 ngmL1, respectively (quality control high,
QCH). Control samples were maintained at room temperature and
analyzed within 24 h as item 2.5. The quality control samples were
analyzed as described above in triplicate on each of 5 days. Within-
assay precision and between-day precision were calculated by one-
way ANOVA with the grouping variable “day” and were expressed as
CV%. Accuracy was deﬁned as the percentage of the nominal con-
centration represented by the concentration estimated with the
calibration curve. The acceptance criteria for accuracy were mean
values within 715% of the theoretical value and for precision a
maximum CV of 15% was accepted [20].
2.10. Lower limit of quantiﬁcation
An independent DBS quality control sample at the lowest point
of the calibration curve at concentrations of 7.5; 15.0; 1.0;
0.5 ng mL1 for TAM, NDT, EDF and HTF, respectively, was
included in the accuracy and precision experiments (quality
control at the limit of quantitation, QCLOQ) and was tested in
triplicate in three different days. The acceptance criteria estab-
lished for the limit of quantiﬁcation was accuracy within
100720% of the nominal value and an imprecision with of
maximum 20% [20].
2.11. Inﬂuence of hematocrit on analytes concentrations assayed
in DBS samples
Aliquots of blood containing different Hct% (25, 30, 35, 40, 45 and
50%) were prepared by centrifuging EDTA whole blood and then
combined with appropriate volumes of cells and plasma. TAM and
metabolites were added to these aliquots of blood to achieve
concentrations of QCL: 21.0; 45.0; 3.0 and 1.8 ngmL1 and QCH:
210.0; 450.0; 30.0 and 18.0 ngmL1 for TAM, NDT, EDF and HTF,
respectively, which were then pipetted onto Whatman 903 paper,
followed by drying at room temperature for 3 h. The DBS obtained
were analyzed in triplicate for each concentration and Hct% as
described in item 2.5. The inﬂuence of the Hct% on TAM and
metabolites measurements was determined as the percentages of
nominal concentrations that were actually measured in the DBS.
2.12. Matrix effect and extraction yield
Matrix effect was evaluated by a post-extraction spike method.
Three series of quality control samples (QCL, QCM and QCH) were
prepared in order to assess extraction yield and matrix effect on
ionization as follows: (A) solutions of TAM, metabolites and IS prepared
in mobile phase solutions in order to obtain ﬁnal concentrations
equivalent to 100% extraction yield and directly injected onto column.
(B) DBS extracts samples from 5 different sources (mixed before
application on paper), post-extraction spiked with TAM, metabolites
inmobile phase containing IS. (C) DBS extracts samples from 5 different
sources (mixed before application on paper) enriched with TAM and
metabolites before extraction. Each quality control sample was ana-
lyzed in quintuplicate. Matrix effect (ME) on ionization was estimated
as the percentages of reduction or increase of TAM, NDT, EDF, HTF and
IS areas on post-extraction spiked (B), comparing to directly injection of
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solutions (B), calculated as ME¼[100%(B/A%)]. Extraction yields (EY)
were calculated comparing the analyte/IS area ratio before extraction
(C) and after extraction (B), using the formula EY¼C/B%.
2.13. Application of the method
The study was conducted in accordance with the Declaration of
Helsinki and was approved by the Research Ethics Committee at the
Hospital de Clínicas de Porto Alegre. A total of 91 patients on adjuvant
hormonal treatment with tamoxifen (20 mg day1) for at least
4 months were enrolled in the study with informed consent. Data
on age, weight, body mass index (BMI), race, compliance (obtained
from the number of TAM tablets taken monthly) and menopause
status were recorded, in addition to the duration of TAM therapy and
any concomitant therapies considered as CYP2D6 inhibitors. Blood
samples were taken 18–24 h after the last TAM intake, patients being
fasten for 4 h. Capillary blood was collected after ﬁnger prick using a
2.0 mm penetration, 0.8 mm blade contact-activating lancet
(Medlances). Blood spots were collected on 2 circles of the Whatman
903 DBS card and allowed to dry for at least 3 h at room temperature.
Fig. 1. Chromatograms obtained from DBS and plasma analyses. (A) Plasma EDF 9.9, HTF 1.5, NDT, 188.3, TAM 111.8 (ng mL1); (B) dried blood spot EDF 4.8, HTF 1.2, NDT,
166.0, TAM 100.0 (ng mL1). Transitions: EDF 374-58 (m/z), HTF 388-72 (m/z), IS 406-100 (m/z), NDT 358-58 (m/z) TAM 372-72 (m/z).
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Analyses were performed within 3 days. Venous blood was simulta-
neously collected within an interval of 715min by venipuncture into
two EDTA tubes. One tube was used for Hct% determination, the other
was immediately centrifuged and plasma was transferred to poly-
propylene tubes, stored at 70 1C until analysis within one month.
Concentrations of TAM, NDT, EDF and HTF were measured through
daily calibration curves and estimated plasma concentrations (EPC)
were obtained after adjustment of DBS concentrations by patients Hct
% and use of a correction factor, as follows:
EPC¼ DBS concentrationð Þ= 1–Hctð Þ  correction factor
Correction factors were estimated so that the ratio of mean DBS
to mean plasma levels would be equal to 1.
2.14. Determination of TAM and metabolites in plasma
A 0.2 mL aliquot of plasma was transferred to screw cap glass
tube and 0.1 mL of the IS solution (clomiphene 0.01 mg mL1),
0.1 mL of Tris buffer pH 10 and 2 mL of extraction solvent (hexane:
n-propanol 95:5, v/v). After homogenization for 30 min and
centrifugation at 3000g for 10 min, a 1.6 mL aliquot of the super-
natant was transferred to a polypropylene microtube and dried at
55 1C for 15 min under air stream. The extract was resuspended
with 0.15 mL of mobile phase and a 25 mL aliquot was injected into
the LC–M/MS system. The chromatographic conditions and mass
detector parameters were the same as those used for the DBS
samples. Concentrations were calculated with daily calibration
curves. The method was linear from 0.5 to 600 ng mL1 with LLOQ
of 7.5 ng mL1 for TAM, 15 ng mL1 for NDT, 1 ng mL1 for EDF
and 0.5 ng mL1 for HTF. Accuracy and imprecision were accep-
table with accuracy of 90.7–107.5%, and percent coefﬁcient of
variation within and between assay in the range of 4.8–13.4.
2.15. Statistical analysis
Initially, a descriptive analysis of the study variables was
conducted. The precision validation parameters were evaluated
using ANOVA. Medians and 25% and 75% percentiles for TAM, NDT,
EDF, HTF levels and metabolic ratio [NDT]/[EDF] were determined.
Analytes in DBS (y) vsmeasured plasma concentrations (x), as well
as estimated plasma (y) vs measured plasma concentrations (x)
were assessed by Passing–Bablok regression [21] and Spearman
correlation. The presence of outliers and tendencies were evalu-
ated using Bland Altman plots [22] of estimated plasma concen-
trations vs measured plasma concentrations as well as DBS vs
measured plasma concentrations. Acceptation criteria for the
agreement between estimated and measured plasma concentra-
tions were based on the guideline on Bioanalytical Method
Validation of the EMA, the difference in concentration should be
within 720% of their mean for at least 67% of the samples [23].
The effect of concomitant CYP2D6 inhibitors was tested for TAM,
NDT, EDF, HTF and metabolic ratio [NDT]/[EDF] from measured and
estimated plasma data obtained from patients stratiﬁed in 2 cohorts
based on the use or not of CYP2D6 inhibitors by Mann–Whitney test.
DBS levels of EDF and the DBS metabolic ratio [NDT]/[EDF] were
further compared between these 2 cohorts with plasma EDF above or
below the threshold of efﬁcacy of 5.9 ng mL1 by Mann–Whitney test.
Analyses were conducted using SPSS version 17.0 and MedCalc version
12.3, Po0.05 was considered statistically signiﬁcant.
3. Results and discussion
3.1. Chromatography and preparation of samples
The LC–MS/MS system proved to be an appropriate system for
determination of TAM and its main metabolites in DBS samples.
TAM, NDT, HTF and EDF are structurally very similar, with
demethylation and/or hydroxylation, resulting in slight differences
of polarity. Reversed phase C18 columns appeared appropriate to
separate TAM metabolites [24]. In this study an Acquitys C18
column (1502.1 mm, 1.7 mm) was used, separating TAM and the
3 metabolites in a 8 min run, with reduced mobile phase con-
sumption of 3.2 mL per analysis. Retention times were 2.77 min
for EDF, 3.02 min for HTF, 5.85 min for IS, 6.07 min for NDT and
Table 1
Method validation parameters, linearity, precision, accuracy and extraction yield and benchtop stability.
Analyte Linear regression
weighting factor 1/x
Quality
control
Nominal
concentration
(ng mL1)
Precision (CV
%)
Accuracy
(%)
Extraction
yield (%)
Ion suppression/
enhancement (%)
Concentration
change after 12 h
(%)
Intra-
assay
Inter-
assay
Tamoxifen y¼0.613x0.403
r¼0.996
LLOQ 7.5 9.09 7.01 93.9 – –
QCL 21.0 8.95 6.31 100.2 89.8 20.4 3.9
QCM 70.0 5.13 8.58 98.5 91.3 24.2 –
QCH 210.0 8.18 5.10 102.8 93.4 24.0 8.1
N-desmethyltamoxifen y¼0.222x0.1913
r¼0.997
LLOQ 15.0 7.93 10.04 92.0 – –
QCL 45.0 6.73 7.61 99.5 81.5 34.4 0.8
QCM 150.0 6.75 8.51 99.4 88.5 34.5 –
QCH 450.0 9.10 5.17 94.5 84.5 35.3 3.2
(Z)-Endoxifen y¼0.117x0.0701
r¼0.991
LLOQ 1.0 7.46 11.48 97.5 – – –
QCL 3.0 6.59 7.68 96.7 47.9 11.1 9.2
QCM 10.0 8.72 10.77 105.2 48.5 11.3 –
QCH 30.0 12.30 6.53 98.0 46.1 12.0 2.7
4-Hydroxytamoxifen y¼0.533x0.0912
r¼0.991
LLOQ 0.5 12.07 7.93 90.6 – – –
QCL 1.8 8.98 11.54 94.6 38.1 5.9 5.2
QCM 6.0 10.42 5.75 110.3 39.4 6.6 –
QCH 18.0 8.53 7.13 98.9 41.2 2.7 5.8
Clomiphene (IS) LLOQ –
QCL þ9.1
QCM þ6.7
QCH þ8.7
LLOQ: lower limit of quantiﬁcation, QCL: quality control low, QCM: quality control medium, QCH: quality control high. (linearity n¼42, precision and accuracy n¼45,
extraction yield n¼30, ion suppression n¼30).
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6.31 min for TAM. Fig. 1 illustrates chromatograms from DBS and
plasma samples.
No interfering compounds were identiﬁed in the 6 DBS samples
processed free from TAM and analytes. Additionally, the tandem
mass spectrometry results in inherent speciﬁcity analysis, in which
chromatograms are monitored through the transition of molecular
ion to three products (1 quantifying and 2 conﬁrmatory ions).
Sample preparation was simple, based on ultrasound-assisted
liquid extraction of analytes from paper punches containing
approximately 90 mL of blood. Extraction yield was higher for the
least polar compounds, with average of 91.5% for TAM and 84.8%
for NDT, comparing to 47.5% for (Z)–(Z)–EDF and 39.6% for HTF.
Besides the lower extraction recoveries of EDF and HTF, the
method presented satisfactory sensitivity considering the extent
of concentrations found in clinical samples, with LLOQ of
1.0 ng mL1 for EDF and 0.5 ng mL1 for HTF [25,14,11,26].
3.2. Method validation
Extracts from DBS containing TAM and metabolites at QCL and
QCH concentrations were stable during the 12 h bench stability
test, with maximum variation in analytical response of 9.2%,
indicating that large batches can be analyzed without taking
special measures to preserve extracts. Calibration data exhibited
signiﬁcant heteroscedasticity, with Fexp ranging from 495.1 to
1237.0 (Ftab (6; 5; 0.95)¼4.95). The regression using a weighting
factor of 1/x offered the best ∑%RE of the models tested, with
values below 1109 and this weighting factor was used for all
subsequent validation tests and for analysis of the clinical samples.
The coefﬁcients of correlation were above 0.99 for all weighting
factors. The results of the precision and accuracy experiments,
assessed by analyzing low, medium and high concentration quality
control samples, were satisfactory, as shown in Table 1. Intra-assay
imprecision were in the range of 5.13 to 12.30% and inter-assay
imprecision was 5.10 to 11.54%, demonstrating that the method is
adequately repeatable. Accuracy was estimated at 94.6 to 110.3%,
which is also within the limits of acceptance for bioanalytical
methods recommended by Shah et al. [20]. The quality control
samples at the lower limit of quantiﬁcation (LLOQ) of 7.5; 15; 1.0;
0.5 ng mL1 for TAM, NDT, EDF and HTF presented acceptable
imprecision (from 7.01 to 12.07%) and accuracy (90.6 to 97.5%).
Due to its high speciﬁcity and sensitivity LC–MS/MS is con-
sidered as the method of choice for quantitative analysis of
compounds in biological matrices. However molecules originating
from the sample matrix that coelute with the compounds of
interest can interfere with the ionization process, causing ion
suppression or enhancement [27]. Post-extraction spiked method
analysis showed (Z)–EDF and HTF ionization suppression within
12% and IS ionization enhancement effect of 8%, indicating that co-
eluting matrix components appear to have a minimal effect on the
considered analytes. TAM and NDT demonstrated to be more
affected by matrix effect with average suppression of 22.9 and
34.7% respectively. Similar observation was pointed out on a
previously described LC–MS/MS method [28], where matrix ioni-
zation suppression (plasma samples) was larger for NDT (38% area
reduction) comparing to other TAM metabolites.
As reported above, matrix components do inﬂuence to some
extent TAM and NDT ionization and consequently the overall
process efﬁciency, requiring therefore the preparation of calibra-
tion and control samples in a DBS matrix reﬂecting at best the
composition of the samples to be analyzed. More important that
the absolute matrix effect, no signiﬁcant variability among con-
centrations and samples was observed in our method. Addition-
ally, TAM and NDT presented high extraction yields (481%),
allowing analysis with satisfactory sensitivity and linearity range
comprising clinical samples concentrations after a 20 mg/daily
intake of TAM [25,11,26].
Thermal stability was also tested in DBS samples at the
concentrations of QCL and QCH after storage at 20 1C, 25 1C
and 45 1C up to 20 days. These temperatures were selected to
simulate conditions that samples sent by regular mail could
potentially be exposed. No changes were observed neither for
TAM nor for NDT on DBS stored over a period of 20 days at
the tested temperatures (maximum variance of 14%). However,
(Z)–EDF and HTF were stable at 20 and 25 1C (maximum
variance of 15%) but not at 45 1C, with an increase on concentra-
tions, which ranged from 38% at day 2, to 47% after 20 days. In
absence of any data in the literature regarding TAM and metabo-
lites stability on DBS samples, we assumed that increase of
metabolite concentrations at higher temperature could be the
consequence of TAM and NDT degradation. Tested EDF and HTF
levels were approximately 10 fold lower than TAM and NDT,
therefore more likely affected by any minor changes in TAM and
NDT concentrations. Another possible explanation for this ﬁnding
could be the production of isobaric interfering compounds on DBS
samples under high temperatures. Both hypotheses should be
further tested.
Information about the thermal, light, and chemical stability of
the analytes in DBS matrix must be available in order to explore its
logistic advantages. When using transport by regular mail it is
important to be aware that the inner temperature of mailboxes in
full sun exposure can reach about 60 1C in summer months [29].
Up to now there is no data in the literature regarding the stability
of EDF and HTF in DBS samples. Considering our ﬁndings on EDF
and HTF stability and the high temperatures during summer time,
it is reasonable to recommend that temperature during transport
and storage of DBS cards for TAM and metabolites measurement
should be controlled and not exceed 25 1C.
Table 2
Patients demographic characteristics (N¼91).
Characteristic (N¼91)
Age (years)
Mean (7SD) 56.3 (10.1)
Range 28–78
Hematocrit (%)
Mean (7SD) 36.0 (2.4)
Range 30.6–43.5
Race/ethnicity (n)
Caucasian 75
Others 16
Menopause status (n)
Pre menopause 41
Post menopause 50
Tamoxifen duration (months)
Median (Percentiles 25–75) 15 (9–23)
Range (4–45)
Marital status (n)
Single 14
Married 45
Divorced 12
Widowed 20
CYP2D6 inhibitor drug (n)
Weak/moderately 11
Strong 7
Adverse effects (n) no/yes
Hot ﬂashes 44/47
Vaginal bleeding 88/3
Vaginal discharge 60/31
Vulvar Itching 73/18
Nausea or vomiting 76/15
Dizzeness 75/16
Cutaneous rash 82/9
Alopecia 68/23
Thrombosis 87/4
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3.3. Impact of hematocrit on determination of TAM and metabolites
The impact of different Hct% levels on calculated concentra-
tions of TAM and metabolites during analysis of DBS samples was
tested at concentrations of QCL and QCH prepared in blank blood
with Hct% ranging from 25 to 50 and quantiﬁed by analytical
curves prepared using blood with Hct% of 35. Variation from
nominal concentrations found in control samples were within
713% for Hct 25%, 710% for Hct 30%, 710% for Hct 35%, 78% for
Hct 40%, 716% for Hct 45% and 720% for Hct 50%. Highest
variations from target were found at Hct 45% and 50% and were
above 15% which was the cutoff for acceptability. This is probably
due to increased viscosity of the blood and hence reduced
dispersion through the paper. In contrast, DBS prepared with
blood with Hct percentages ranging from 25 to 40 presented
results within the range of acceptability (87–108%). On this basis,
analytical curves prepared using blood with Hct% of 35 are
applicable to samples from patients with Hct% within 25–40,
covering most of patients Hct% range (30.6 to 43.6, mean 36).
Seven patients had Hct% above 40, where calculated concentra-
tions have to be corrected accordingly.
Besides DBS samples being obtained from capillary blood,
venous blood was used to determine the patient Hct%, considering
the absence of difference between capillary and venous Hct% [29].
Yang et al. [30] also found no difference between Hct% measured
in venous and capillary blood.
3.4. Clinical application and method comparison
A total of 91 patients on adjuvant hormonal treatment with
tamoxifen (20mg day1) were enrolled in this study. Patient’s
demographic and clinical data are presented in Table 2. All patients
were classiﬁed as adherent to TAM, with reported use of 30 tablets
monthly. The patient population displayed a mean age of 56.3 years,
mean BMI of 27.0 kg m2 and mean Hct% of 36.0 (range 30.6–43.5), 75
patients were Caucasian and 16 were brown (parda-a Brazilian national
census classiﬁcation) or black. Hot ﬂashes were the major adverse
effect (51.6%). Eighteen patients (19.8%) reported concomitant use of
CYP2D6 inhibitors drugs: 11 on weak inhibitors (e.g. venlafaxine,
citalopram and haloperidol) and 7 on strong inhibitors (e.g. ﬂuoxetine
and bupropion).
The developed method was used to analyze DBS concentrations
of TAM and its metabolites, paired with plasma analyses. Analytes
concentrations were highly variable in both matrices, as presented
in Table 3. Median DBS levels in the whole cohort were: TAM
100.0 ng mL1; NDT 202.0 ng mL1, (Z)–EDF 5.9 ng mL1 and HTF
0.9 ng mL1 and median plasma concentrations were: TAM
123.2 ng mL1; NDT 263.5 ng mL1, EDF 9.1 ng mL1 and HTF
1.4 ng mL1. Plasma trough concentrations were consistent with
those previously reported in the literature [25,11,26]. EDF levels
were 6.5-fold higher than HTF concentrations, with the 5.7-fold
[14] and 6.8-fold [31] previously reported, conﬁrming the pre-
dominance of EDF over HTF.
Tamoxifen, NDT, EDF and HTF concentrations in DBS were in
average 80%, 77%, 59% and 72% of those measured in plasma. EPC
were calculated from DBS concentrations after adjustment by patients
Hct% and using the correction factors of 0.84; 0.78; 1.12; 0.87 for TAM,
NDT, EDF and HTF respectively. After Hct% and factor correction,
median estimated plasma levels were: TAM 123.3 ng mL1; NDT
267.9 ng mL1, EDF 10.0 ng mL1 and HTF 1.3 ng mL1, thus esti-
mated levels represented in average 98 to 104% of the actually
measured plasma concentrations. The differences between EPC and
Table 3
Patients median, percentiles, range and correlations of TAM, NDT, EDF, HTF, and metabolic ratio [NDT]/[EDF] concentrations in plasma, dried blood spot and estimated
plasma (N¼91).
Analyte Sample Median (P25–
P75) (ng mL1)
Range
(ng mL1)
Mean7SD relation to
measured plasma (%)
Passing Bablok regression to
measured plasma
Spearman correlation to
measured plasma (rs)
Tamoxifen Measured
plasma
123.2 (101.5–
165.5)
52.6–307.8 – – –
Dried
blood spot
100.0 (82.58–
123.0)
40.0–
290.0
80711 y¼0.688xþ0.872 (P¼0.65) 0.917nn
Estimated
plasma
123.3 (101.4–
154.1)
49.9–
364.3
98714 y¼0.982xþ0.804 (P¼0.69) 0.911nn
N-desmethyltamoxifen Measured
plasma
263.5 (188.3–
353.0)
85.6–
575.9
– – –
Dried
blood spot
202.0 (140.0–
262.1)
76.3–
504.0
77714 y¼0.739xþ9.592 (P¼0.20) 0.883nn
Estimated
plasma
267.9 (177.4–
350.0)
104.4–
664.3
102719 y¼1.018xþ3.854 (P¼0.39) 0.877nn
(Z)-Endoxifen Measured
plasma
9.1 (5.8–15.1) 2.4–40.3 – – –
Dried
blood spot
5.9 (3.1–9.0) 1.0–24.2 59717 y¼0.566x0.041 (P¼0.31) 0.895nn
Estimated
plasma
10.0 (5.2–15.4) 1.5–41.3 104730 y¼1.053x0.4376 (P¼0.35) 0.897nn
4-Hydroxytamoxifen Measured
plasma
1.4 (0.9–1.8) 0.7–3.9 – – –
Dried
blood spot
0.9 (0.6–1.3) 0.5–3.2 72718 y¼0.761xþ0.008 (P¼0.31) 0.842nn
Estimated
plasma
1.3 (0.8–1.8) 0.5–4.4 99725 y¼1.061x0.012 (P¼0.33) 0.839nn
Metabolic ratio [NDT]/[EDF] Measured
plasma
25.8 (16.3–45.9) 5.1–175.4 – – –
Dried
blood spot
37.5 (19.6–67.9) 7.4–230.7 139741 y¼1.508x3.308 (P¼0.63) 0.895nn
Estimated
plasma
28.1 (14.7–50.9) 5.5–173.0 105731 y¼1.120x2.134 (P¼0.71) 0.897nn
NDT: N-desmethyltamoxifen; EDF: endoxifen; P25: percentile 25; P75: percentile 75, rs: spearman correlation coefﬁcient.
P value as Cusum test for linearity.
nn Po0.01 Spearman correlation.
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measured plasma concentrations were within 720% for most sam-
ples, 87 (97%) TAM, 86 (95%) NDT, 73 (80%) EDF and 80 (88%) HTF,
being in accordance with the EMA acceptation criteria for the
agreement between methods [23].
DBS concentrations and EPC were highly correlated to mea-
sured plasma concentrations with rs40.83 (Po0.01) for all
associations. Passing–Bablok regressions were performed in order
to evaluate the existence of constant and/or proportional errors.
Comparison of DBS (y) and measured plasma (x) concentrations
returned in intercept 95% conﬁdence intervals of 0.6472 to
10.0400 for TAM, 9.1216 to 28.0722 for NDT, 0.5097 to
0.4635 for EDF, 0.09409 to 0.09373 for HTF and 5.9314 to
0.3608 for the ratio [NDT]/[EDF] indicating no constant error.
However, slope 95% conﬁdence intervals showed the presence of
proportional difference between methods: 0.6086 to 0.7879 for
TAM, 0.6577 to 0.8289 for NDT, 0.4979 to 0.6402 for EDF, 0.6598 to
0.8512 for HTF and 1.3389 to 1.6789 for the ratio [NDT]/[EDF].
When EPC (y) and measured plasma levels (x) were compared,
intercept 95% conﬁdence intervals were 11.8954 to 17.8583 for
TAM, 30.1816 to 26.4940 for NDT, 1.0641 to 0.7439 for EDF and
0.1460 to 0.1349 for HTF, indicating no constant error. At this
evaluation, slope 95% conﬁdence intervals showed to have no
proportional differences: 0.8343 to 1.1120 for TAM, 0.9113 to
1.1465 for NDT, 0.9205 to 1.1744 for EDF, and 0.9289 to 1.1778 for
HTF, indicating that when the effect of Hct% and multiplication
factor are taken into account, methods are comparable. Cusum test
P values were all 40.05, indicating no signiﬁcant difference from
linearity.
Estimated plasma concentrations (EPC) of TAM and metabolites
were also compared to measured plasma concentrations (MPC)
by Bland–Altman plots (Fig. 2). The mean difference of the
concentrations in plasma and estimated plasma concentrations
using individual Hct% were 4.0 ng mL1 for TAM, 0.7 ng mL1
for NDT, 0.0 for EDF and 0.06 ng mL1 for HTF, with only 4, 5 and
3 values (out of 91) outside the 71.96 standard deviation range
for TAM and NDT, EDF and HTF, respectively. Moreover, differences
were also distributed randomly around the mean, indicating the
absence of systematic errors which were proportional to TAM and
metabolites levels.
Our data showed a wide range of EDF plasma concentrations
among patients, with a 16.8 fold difference between the lowest
(2.4 ng mL1) and the highest (40.3 ng mL1) measurement. The
amplitude of concentrations may be attributed to the interindivi-
dual pharmacokinetic variability, including polymorphisms of
CYP2D6 and CYP3A4 and drugs interactions [1,2,4–7]. Thus, we
evaluated the impact of CYP2D6 inhibitors on EDF levels and
[NDT]/[EDF] metabolic ratio in both matrices and found reduced
metabolites concentrations in patients under concomitant use of
CYP2D6 inhibitors drug inhibitors (Table 4) as compared to the
group without use of drug inhibitors, as follows: median DBS
Fig. 2. Method comparison, Bland Altman plot of estimated plasma vs measured plasma concentrations of TAM (A), NDT (B), EDF (C) and HTF (D) in clinical samples (N¼91).
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3.5 ng mL1 vs 5.8 ng mL1, EPC 6.1 ng mL1 vs 10.2 ng mL1 and
measured plasma 5.5 ng mL1 vs 10.1 ng mL1 (Po0.05 in DBS
and EPC, and Po0.01 in measured plasma). Moreover, the fre-
quency of patients with EDF levels below the threshold of optimal
clinical activity (5.9 ng mL1) was higher in patients taking
CYP2D6 inhibitor drug, 50% (9 of 18), compared to patients
without CYP2D6 inhibitors, 20.5% (15 of 73) (Fisher Exact test,
Po0.05).
The metabolic ratio [NDT]/[EDF], depending on CYP2D6 meta-
bolism, was also affected by the use of drug inhibitors, as observed
in both matrices: median DBS 40.5 vs 32.0, EPC 24.0 vs 40.5 and
measured plasma 20.8 vs 53.3 for patients taking or not inhibitors
respectively (Po0.05 in DBS and EPC, and Po0.01 in measured
plasma). Thus, DBS based monitoring method showed to have
equivalent capacity to identify differences on EDF levels and
metabolic ratio between CYP2D6 metabolism affected or not by
drug interactions as does the usual plasma measurement.
Based on these ﬁndings, it was interesting to evaluate if it was
possible to identify, through DBS samples, patients with EDF
plasma levels below 5.9 ng mL1. Overall, 24 patients (26.4%)
had EDF measured plasma concentrations o5.9 ng mL1, of these
23 (96%) also presented estimated plasma concentrations below
the threshold. Only 4 patients with estimated plasma concentra-
tions o5.9 ng mL1 had measured plasma concentrations above it
(6.07 ng mL1, 6.18 ng mL1, 6.48 ng mL1 and 7.94 ng mL1),
but still close to the threshold. Thereafter, using Passing–Bablok
regression equation, we extrapolated the plasma EDF threshold to
DBS concentration and found a proposed DBS threshold of
3.3 ng mL1 (Fig. 3). Using the DBS proposed threshold, as
previously observed on estimated plasma results, we were able
to identify 23 of 24 samples with measured plasma concentrations
o5.9 ng mL1. The high prevalence of patients with low EDF
levels could be related to the high frequency of use of inhibitor
drugs (20%) and other factors such as genetic polymorphisms of
CYP2D6 and/or other enzymes to be further evaluated.
Additionally we compared DBS and estimated plasma EDF con-
centrations between groups of measured EDF above or below
5.9 ng mL1 and found reduced levels at the last group as well:
median EDF DBS 2.0 ng mL1 vs 7.0 ng mL1 and 3.6 ng mL1 vs
12.5 ng mL1 (Po0.01), for DBS and estimated plasma respectively.
Similarly DBS and estimated plasma [NDT]/[EDF] metabolic ratio
were also signiﬁcantly different between groups of EDF plasma levels
Table 4
Endoxifen levels and metabolic ratio of [NDT]/[EDF] in patients taking or not CYP2D6 inhibitor drugs and according to EDF plasma threshold 5.9 ng mL1 (N¼91).
Patients n Endoxifen DBS
(ng mL1)
Estimated plasma
Endoxifen
(ng mL1)
Measured
plasma
Endoxifen
(ng mL1)
DBS [NDT]/[EDF] Measured
plasma [NDT]/
[EDF]
Estimated
plasma [NDT]/
[EDF]
Median (P25–P75)
No CYP2D6 inhibitor
drug
73 5.8 (3.3–9.2) 10.2 (5.9–16.2) 10.1 (6.2–15.5) 32.0 (12.9–42.8) 20.8 (14.6–41.7) 24.0 (13.0–42.8)
Taking CYP2D6
inhibitor drug
18 3.5 (2.1–6.7) 6.1 (3.7–11.6) 5.5 (4.0–8.4) 40.5 (27.8–73.8) 53.3 (34.1–69.5) 40.5 (27.8–73.8)
P o0.05 o0.05 o0.01 o0.05 o0.01 o0.05
Plasma EDF
o5.9 ng mL1
24 2.0 (1.9–2.5) 3.6 (3.2–4.4) – 90.2 (61.3–144.1) 67.5 (42.7–91.5) 67.3 (45.9–108.0)
Plasma
EDFZ5.9 ng mL1
67 7.0 (4.9–9.5) 12.5 (9.2–16.4) – 28.6 (16.6–39.7) 19.7 (13.6–31.4) 21.4 (12.5–29.7)
P o0.01 o0.01 – o0.01 o0.01 o0.01
P value as Mann–Whitney test.
Fig. 3. Correlation of EDF concentrations in DBS and plasma (A); correlation of estimated plasma EDF concentration and EDF measured plasma concentration (B) (N¼91).
Dashed lines indicate EDF minimum therapeutic threshold concentration in plasma (5.9 ng mL1) [8] and proposed EDF concentration threshold in DBS, extrapolated from
plasma concentrations (3.3 ng mL1).
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(Table 4). In summary, the DBSmethod was able to identify with high
accuracy (96%) patients with plasma EDF levels below the clinical
threshold related to better prognosis as well as impaired CYP2D6
metabolism through [NDT]/[EDF] metabolic ratio.
4. Conclusions
A method for determination of TAM and its major metabolites
in DBS using LC–MS/MS was developed and validated. Transport
and storage of DBS samples require special attention, since EDF
and HTF concentrations in control samples increased after storage
at 45 1C. TAM, NDT, EDF, HTF concentrations in DBS and estimated
plasma were highly correlated to measured plasma concentra-
tions. We found a high prevalence of patients with EDF level below
the clinical threshold of 5.9 ng mL1 which were effectively
identiﬁed through DBS samples. These ﬁndings suggest that DBS
based therapeutic monitoring of TAM can be an efﬁcient tool to
optimize adjuvant breast cancer treatment, allowing patients to
collect blood samples at their home within the appropriate time to
obtain trough samples, facility transport conditions and handling
safety. In addition, our results also offer insight into the effects of
CYP2D6 inhibitors on TAM metabolism to EDF.
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